Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
summarizeSummary
Moderna has updated its financial outlook, now expecting 2026 year-end cash and cash equivalents to be in the range of $4.5 billion to $5 billion, with total projected liquidity between $5.4 billion and $5.9 billion. Critically, the company also anticipates recording a significant $950 million charge in the first quarter of 2026 related to a settlement payment. This update provides more specific forward-looking financial details following the 10-K filed on February 20th, which outlined 2025 results and broader financial plans. While the $950 million charge is a material one-time expense impacting Q1, the strong projected liquidity and the company's stated path to revenue growth in 2026 and breakeven by 2028 offer a balanced view of its financial health. Traders will be watching for further details on the settlement and progress towards these financial targets in upcoming earnings reports.
At the time of this announcement, MRNA was trading at $54.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.7B. The 52-week trading range was $22.28 to $55.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.